Merck’s Bio-Techne acquisition strengthens fundamentals yet stock price appears fairly valued now

Merck strengthens its life sciences portfolio with Bio-Techne, but analyst consensus suggests investors should wait for a better entry point.
M and A strategies for startups

Merck strengthens its life sciences portfolio with Bio-Techne, but analyst consensus suggests investors should wait for a better entry point.

Multiple herbal brand mergers show strong financial results in early quarters, suggesting consolidation is unlocking real synergies and cash flow across the sector.

Acquisition offers represent a fundamental inflection point for scientific and technology startups: they can accelerate innovation timelines by years,...

Scientific software companies are experiencing unprecedented valuation levels as acquisition discussions intensify across the sector.

Pepper's March 2026 acquisition of Y Combinator-backed Alima represents a significant strategic move that strengthens the company's position in AI-driven...

Child-friendly robots are attracting corporate acquisition interest because they represent a rare convergence of consumer demand, technological viability,...

When a celebrity purchases a historic property at a significant price, the expectation often follows: the value should appreciate over time.